Syndrome d’hyperémèse cannabinoïde
Revu par Dr Colin Tidy, MRCGPRédigé par Dr Hayley Willacy, FRCGP Publié à l'origine 10 fév 2026
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
Professionnels de la santé
Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de la santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver l'un de nos articles de santé plus utile.
Contexte
Cannabinoid hyperemesis syndrome (CHS) is a functional gastrointestinal disorder characterised by recurrent episodes of severe nausea, vomiting, and abdominal pain in the context of chronic, heavy cannabis use.1
A distinctive feature is temporary symptom relief with hot bathing or showering. Symptoms resolve with sustained cessation of cannabis.
Épidémiologie
Increasingly recognised with rising cannabis availability and greater availability of more potent products over the last 20 years.2
In the UK, cannabis is the most commonly used illicit drug, with 7.4% of adults between 16- to 59-years-old reporting having used the drug within the past year.3
As of December 2024, all but four states in the United States have full or partial legal cannabis laws or decriminalisation laws in effect. 2.6 million Americans become new users each year; the majority of this group is under the age of 19.4
CHS typically affects individuals younger than 50 years, with a median age of 28 years. Notably, the median age for cannabis initiation in these patients is 16, suggesting that early cannabis use may play a role in CHS development.4
Prevalence is uncertain but likely underdiagnosed due to overlap with other vomiting syndromes and underreporting of cannabis use.
Pathogenèse5
CHS typically develops after years of frequent (often daily) cannabis use, including smoked, vaped, or edible forms.
The exact mechanism of CHS is not fully understood, but several theories exist:
Endocannabinoid system dysregulation: Chronic overstimulation of cannabinoid (CB1) receptors may paradoxically impair central antiemetic effects and delay gastric emptying.
Hypothalamic effects: Cannabinoids may disrupt thermoregulation, explaining the compulsive hot bathing behaviour.
Peripheral gastrointestinal effects: CB1 receptor activation in the gut may reduce motility and promote nausea and vomiting.
Genetic susceptibility: Not all chronic cannabis users develop CHS, suggesting individual vulnerability.6
Présentation
CHS classically progresses through three phases:17
Prodromal phase
Early morning nausea.
Abdominal discomfort.
Fear of vomiting.
Continued cannabis use.
Hyperemetic phase
Persistent, severe nausea and vomiting.
Abdominal pain (often epigastric or periumbilical).
Dehydration and weight loss.
Compulsive hot showers or baths for symptom relief.
Symptoms often return within 10-30 minutes after hot-water bathing, which might explain why patients take up to 20 hot showers a day or sit in a hot bath as long as possible.2 In extreme cases, patients will even resort to checking into a hotel to ensure a continuous supply of hot water.
Poor response to standard antiemetics.
Phase de récupération
Resolution of symptoms after cannabis cessation.
Return of normal eating patterns.
Symptoms recur if cannabis use resumes.
Diagnostic
CHS is a clinical diagnosis based on history and exclusion of other causes.
Common diagnostic features include:
Long-term, frequent cannabis use.
Recurrent episodes of intractable vomiting.
Relief with hot bathing.
Resolution of symptoms after cannabis cessation.
The Rome IV criteria support the diagnosis when symptoms are present for ≥3 months with onset ≥6 months prior.12
Laboratory and imaging studies are typically nonspecific and are used to rule out alternative diagnoses. Common findings may include:
Electrolyte abnormalities (eg, hypokalaemia).
Elevated creatinine from dehydration.
Normal imaging studies.
Diagnostic différentiel8
Conditions to consider include:
Cyclic vomiting syndrome (CVS).
Aiguë gastro-entérite.
Gastritis or reflux gastro-œsophagien.
Intracranial pathology (in selected cases).
Distinguishing CHS from CVS relies heavily on cannabis use history and symptom resolution with cessation.
Gestion
Acute phase9
Supportive care: Intravenous fluids and electrolyte correction.
Antiemetics: Traditional agents (eg, ondansetron, metoclopramide) are often ineffective.8
Haloperidol or droperidol: Evidence supports efficacy in reducing vomiting.5
Topical capsaicin: Applied to the abdomen or arms; thought to act via TRPV1 receptors.
Although there is substantial supporting literature for haloperidol use in adults, data on the paediatric population are limited. Benzodiazepines, in particular lorazepam and clonazepam, are the most commonly used drugs, both for their anti-emetic effects and support for cannabis withdrawal symptoms.7
Hot showers or baths: Provide temporary symptomatic relief (not definitive treatment).
Definitive treatment10
Complete cessation of cannabis use is the only proven long-term cure.
Patient education and counselling are critical.
Referral for substance use treatment may be appropriate.
It is important to emphasise that patients may struggle to accept that cannabis is the cause of their symptoms, making cessation challenging.7 CHS often presents comorbidly with attention deficit hyperactivity disorder, anxiety, and depression, and cannabis use is sometimes employed for the self-management of anxiety.
Complications
Les complications potentielles incluent :
Severe dehydration.
Electrolyte disturbances, hypophosphataemia.11
Oesophagitis, Mallory–Weiss tears, pneumomediastinum, oesophageal perforation (Boerhaave syndrome), pneumothorax, and pneumopericardium.1213
Weight loss and malnutrition.
Burns (from hot water).14
Frequent emergency department visits and hospital admissions.
Pronostic1
The prognosis is excellent with sustained cannabis cessation, with most patients experiencing complete symptom resolution within days to weeks. Relapse is common if cannabis use is resumed.
Long-term outcomes depend largely on the patient’s ability to abstain from cannabis and engage in follow-up care.
Mises à jour exclusives pour les professionnels de la santé
Restez informé des dernières mises à jour cliniques, des perspectives professionnelles et des conseils fondés sur des preuves. La newsletter Patient Pro sélectionne des contenus essentiels pour les professionnels de santé—livrés directement dans votre boîte de réception.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.
Lectures complémentaires et références
- Elnagar A, Kgomo M, Mokone M, et al; Cannabinoid hyperemesis syndrome. BMJ Case Rep. 2024 Apr 30;17(4):e256921. doi: 10.1136/bcr-2023-256921.
- Jimenez-Castillo RA, Arumugam S, Remes-Troche JM, et al; Cannabinoid hyperemesis syndrome: A review. Rev Gastroenterol Mex (Engl Ed). 2025 Apr-Jun;90(2):214-226. doi: 10.1016/j.rgmxen.2025.02.002. Epub 2025 Jun 13.
- Ciesluk B, Erridge S, Sodergren MH, et al; Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users. Front Psychol. 2024 Jan 8;14:1279123. doi: 10.3389/fpsyg.2023.1279123. eCollection 2023.
- Peles S, Khalife R, Magliocco A; Cannabinoid Hyperemesis Syndrome: A Rising Complication. Cureus. 2025 Feb 13;17(2):e78958. doi: 10.7759/cureus.78958. eCollection 2025 Feb.
- Russo EB, Whiteley VL; Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure. Front Toxicol. 2024 Oct 23;6:1465728. doi: 10.3389/ftox.2024.1465728. eCollection 2024.
- Russo EB, Spooner C, May L, et al; Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation. Cannabis Cannabinoid Res. 2022 Jun;7(3):336-344. doi: 10.1089/can.2021.0046. Epub 2021 Jul 5.
- Pietrantoni C, Margiotta G, Marano G, et al; Cannabinoid Hyperemesis Syndrome in Adolescents: A Narrative Review. Pediatr Rep. 2025 Jul 14;17(4):75. doi: 10.3390/pediatric17040075.
- Cue L, Chu F, Cascella M; Cannabinoid Hyperemesis Syndrome.
- Borgundvaag B, Bellolio F, Miles I, et al; Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. Acad Emerg Med. 2024 May;31(5):425-455. doi: 10.1111/acem.14911.
- Senderovich H, Patel P, Jimenez Lopez B, et al; A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options. Med Princ Pract. 2022;31(1):29-38. doi: 10.1159/000520417. Epub 2021 Nov 1.
- Nachnani R, Hushagen K, Swaffield T, et al; Cannabinoid Hyperemesis Syndrome and Hypophosphatemia in Adolescents. JPGN Rep. 2022 Sep 1;3(4):e248. doi: 10.1097/PG9.0000000000000248. eCollection 2022 Nov.
- Klazura G, Geraghty JR, Rojnica M, et al; Cannabinoid Hyperemesis Syndrome Complicated by Pneumomediastinum: Implications for Pediatric Surgeons. Clin Surg J. 2022;5(Suppl 13):6-13. Epub 2022 Jul 31.
- Hernandez Garcia LR, Kemper S, Chillag SA; Pneumomediastinum and Pneumorrhachis Associated With Cannabinoid Hyperemesis Syndrome. Cureus. 2022 Dec 10;14(12):e32380. doi: 10.7759/cureus.32380. eCollection 2022 Dec.
- Osagie E, Mirza O; Recurrent Severe Burns Due to Cannabinoid Hyperemesis Syndrome. Cureus. 2023 Feb 2;15(2):e34552. doi: 10.7759/cureus.34552. eCollection 2023 Feb.
À propos du critiqueVoir la biographie complète

Dr Colin Tidy, MRCGP
Médecin généraliste, Auteur médical
MBBS, MRCGP, MRCP (Paediatrics), DCH
Le Dr Colin Tidy est un médecin du NHS, basé dans l'Oxfordshire.
Historique de l'article
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
Next review due: 10 Aug 2030
10 fév 2026 | Publié à l'origine
Écrit par :
Dr Hayley Willacy, FRCGPRevu par
Dr Colin Tidy, MRCGP
Plus sur la santé mentale (psychiatrie)
- Réaction aiguë au stress
- Trouble lié à l’usage de l’alcool : repérage et évaluation
- Abus et intoxication aux amphétamines
- Problèmes de santé mentale prénatale
- Trouble désintégratif de l'enfance
- Soin communautaire
- Abus de drogue de méthamphétamine en cristal
- Délire
- Maladie fabriquée ou induite par les soignants
- Démence frontotemporale
- Trouble d'anxiété généralisée
- Syndrome de Münchhausen
- Crises non épileptiques
- Éjaculation précoce
- Protection des enfants
- Auto-mutilation
- Thérapie sexuelle et conseil
- Soutenir la famille des personnes atteintes de démence
- Chorée de Sydenham
- Conseils pour gérer le bien-être en soins primaires


